Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04210843 · ClinicalTrials.gov registry record · Phase 3
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,033
- Enrollment target
NCT04210843 is a Phase 3 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 1,033 participants.
The verdict
NCT04210843, a Phase 3 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,033 participants
- Enrollment target
Study Summary
The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment. This study also fulfilled the Novartis commitment to provide post-trial access to patients who had completed studies: CQGE031C2302 (NCT03580369), CQGE031C2303 (NCT03580356), CQGE031C2202 (NCT03437278) or CQGE031C1301 (NCT03907878).
Interventions
- DRUG Ligelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,033 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2022-09-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04210843
The ClinicalTrials.gov registry entry for NCT04210843 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,033 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ligelizumab is the first listed.
NCT04210843 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04210843 about?
NCT04210843 is a clinical study titled "Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab". The purpose of this extension study was to establish efficacy and safety of ligelizumab. This was assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who had completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite s...
What is the current status of trial NCT04210843?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,033 participants. The study started on 2020-04-08. Estimated completion is 2022-09-01.
What interventions are being tested in trial NCT04210843?
The interventions under investigation include: Ligelizumab (DRUG).
Who is sponsoring clinical trial NCT04210843?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.